Akcali, CaglarUcar, AsliAtay, Kadri2025-11-152025-11-1520252045-2322https://doi.org/10.1038/s41598-025-16321-whttps://hdl.handle.net/20.500.12514/9923Ucar, Asli/0000-0001-9724-9571;This study was conducted to evaluate the effect of inulin on bowel symptoms, depression and quality of life in individuals with constipation-predominant irritable bowel syndrome. This study was designed as a randomized, single-blind, placebo-controlled clinical trial with a parallel design and a 1:1 allocation ratio. Individuals (n = 34) aged between 21 and 63 years with constipation-predominant IBS were included in the study. Individuals were randomly assigned to two groups: the prebiotic group (n = 17), which received a 50%/50% mixture of inulin/oligofructose (4.6 g twice daily, for a total daily dose of 9.2 g), and the placebo group (n = 17), which total received 9.2 g of maltodextrin per day. The intervention period was 8 weeks. Bristol Stool Scale, IBS-Visual Analogue Scale (IBS-VAS), IBS-Symptom Severity Score Scale (IBS-SSS), IBS-Quality of Life Scale (IBS-QoL) and Beck Depression Scale were administered to the participants at the beginning, 1st month and 2nd month. As a result, total IBS-QoL score increased in the prebiotic group (61.0 +/- 19.4 to 77.4 +/- 15.1; p < 0.006), whereas total IBS-SSS score decreased (267.3 +/- 56.0 to 195.8 +/- 59.0; p < 0.026). In the prebiotic group, significant improvement was observed in the IBS-VAS parameters of constipation status (2.2 +/- 2.3 to 4.9 +/- 2.5; p < 0.042(groupxtime)), psychological state (7 (2-10) to 9 (5-10); p < 0.006). It is thought that inulin may have beneficial effects on reducing symptom severity and frequency and on quality of life in individuals with IBS in whom constipation is predominant.en10.1038/s41598-025-16321-winfo:eu-repo/semantics/openAccessBowel SymptomsDepressionInulinConstipationIrritable Bowel SyndromeQuality of LifeArticle2-s2.0-105017623279